IFAA, in conjunction with Med-IQ and ProPatient, has launched an educational series “Biosimilars For Rheumatoid Arthritis: What Do I Need To Know?,” which not only informs participants of the key differences between biologics and biosimilars, but it also provides helpful tips for patients preparing to have an open, and educated conversation with their healthcare provider.
Patients can choose which topics are of most interest to them, then click on the link to learn more from medical professionals and Tiffany Westrich-Robertson, IFAA's CEO (and RA, axSpA patient, pictured above). Patients can also download the app, which will enable them to record questions they can use to help talk about biosimilars with their practitioner. NOTE: While the series mentions RA, the information is relevant to patients regardless of their diagnosis.
The following questions are addressed in the video education module:
- What is a Biologic? What is a Biosimilar?
- How is a Biosimilar different than a Biologic?
- How are Biosimilars tested for approval on market?
- Is a Biosimilar the same as my current biologic?
- Can I safely switch to a Biosimilar?
- Can I be switched to a Biosimilar if I'm currently taking a Biologic? Can I choose not to change?
- How do I talk to my doctor about Biosimilars?